Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.86% | -8.23% | -23.81% | -24.40% | -28.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.86% | -8.23% | -23.81% | -24.40% | -28.20% |
| Cost of Revenue | 36.76% | 0.47% | -18.15% | -22.87% | -33.39% |
| Gross Profit | -8.74% | -14.17% | -27.95% | -25.56% | -24.11% |
| SG&A Expenses | 4.05% | 2.32% | -0.18% | -3.43% | -7.81% |
| Depreciation & Amortization | -10.64% | -8.97% | -3.70% | 0.46% | -1.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.47% | 1.00% | -7.96% | -11.48% | -18.42% |
| Operating Income | -55.64% | -136.37% | -1,438.82% | -460.65% | -479.90% |
| Income Before Tax | -77.70% | -189.59% | -547.45% | -366.79% | -512.26% |
| Income Tax Expenses | -102.97% | 199.52% | 199.52% | 199.67% | 199.79% |
| Earnings from Continuing Operations | -36.50% | -303.07% | -463.97% | -321.15% | -340.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.50% | -303.07% | -463.97% | -321.15% | -340.53% |
| EBIT | -55.64% | -136.37% | -1,438.82% | -460.65% | -479.90% |
| EBITDA | -227.10% | -1,616.80% | -217.83% | -150.13% | -128.96% |
| EPS Basic | -43.25% | -322.04% | -474.66% | -324.42% | -338.03% |
| Normalized Basic EPS | -88.66% | -221.39% | -529.14% | -328.64% | -399.13% |
| EPS Diluted | -42.65% | -335.10% | -485.47% | -328.31% | -342.95% |
| Normalized Diluted EPS | -88.66% | -217.99% | -534.90% | -330.88% | -404.42% |
| Average Basic Shares Outstanding | -4.44% | -3.85% | -2.81% | -2.30% | -2.11% |
| Average Diluted Shares Outstanding | -4.44% | -4.14% | -3.45% | -2.93% | -2.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |